B. Riley set a $3.00 price objective on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a report released on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on the stock. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, November 14th. Roth Capital restated a buy rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, HC Wainwright restated a buy rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd.

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.64 on Tuesday. Actinium Pharmaceuticals has a 52 week low of $0.54 and a 52 week high of $1.72.

COPYRIGHT VIOLATION NOTICE: “B. Riley Analysts Give Actinium Pharmaceuticals (ATNM) a $3.00 Price Target” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/b-riley-analysts-give-actinium-pharmaceuticals-atnm-a-3-00-price-target/1765459.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.